Duchenne Parent Project España y SOM Biotech renuevan su acuerdo de colaboración
Tras los resultados obtenidos durante el primer año de colaboración, la Asociación Duchenne Parent Project […]
Continue Reading2017: A landmark year for SOM Biotech
As 2017 comes to a close, it is a great time of year for business […]
Continue ReadingWorld Orphan Drug Congress Europe 2017
The 8th annual World Orphan Drug Congress was held in Barcelona on 13-15th of November […]
Continue ReadingSOM Biotech at Bio-Europe 2017
Dr. Raúl Insa (CEO) and Raj Airey (Chief Strategy Officer) had the opportunity to discuss […]
Continue ReadingSOM Biotech at International Symposium on “Rare diseases and Big Data”
Dr. Ferruccio Palazzesi, SOM Biotech Senior Computational Chemist, attended the International Symposium on “Rare diseases […]
Continue ReadingSOM Biotech releases a new version of its proprietary drug repurposing process
Using the latest modular workflow technologies, SOM Biotech has released a new version of his […]
Continue ReadingNippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for bevantolol (Calvan®)
SOM Biotech has determined and validated an entirely new usage for Nippon Chemiphar’s marketed hypertension […]
Continue ReadingSOM Biotech at 2017 ASEBIO Investor Day
SOM Biotech was one of the presenting companies at 2017 ASEBIO Investor Day. ASEBIO Investor Day is […]
Continue ReadingSOM Biotech invited at Chinese-Swiss Health Collaborations Forum
SOM Biotech was one of the companies invited to the Private Chinese-Swiss Investor Collaborations Forum […]
Continue ReadingII Workshop sobre Transferencia del Conocimiento Científico en la Distrofia Muscular de Duchenne
La Compañía SOM Biotech estuvo presente en el II Workshop sobre Transferencia del Conocimiento Científico en la […]
Continue Reading